The estimated Net Worth of Robert W Hooper is at least $50.3 Thousand dollars as of 2 October 2018. Mr. Hooper owns over 10,000 units of Imunon Inc stock worth over $50,347 and over the last 14 years he sold CLSN stock worth over $0. In addition, he makes $0 as Independent Director at Imunon Inc.
Robert has made over 13 trades of the Imunon Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of CLSN stock worth $27,000 on 2 October 2018.
The largest trade he's ever made was buying 25,907 units of Imunon Inc stock on 26 May 2011 worth over $71,762. On average, Robert trades about 3,219 units every 85 days since 2010. As of 2 October 2018 he still owns at least 25,687 units of Imunon Inc stock.
You can see the complete history of Mr. Hooper stock trades at the bottom of the page.
Robert W. Hooper is Independent Director of Celsion Corporation since July 29, 2010. Mr. Hooper is currently President of Crows Nest Ventures, Inc. a privately held company, which provides advisory and consulting services to the healthcare industry. From 1997 to 2001, Mr. Hooper served as President North America for IMS Health Incorporated, a healthcare information and market research company listed on The New York Stock Exchange. From 1993 to 1997, he served as President of Abbott Laboratories Canada. From 1989 to 1993, he served as Managing Director, Australia/Asia for Abbott Laboratories. Prior to that, he held increasingly senior positions at E.R. Squibb and Sterling Winthrop Labs. Mr. Hooper holds a B.A degree in Biology from Wilkes University.
Robert Hooper is 68, he's been the Independent Director of Imunon Inc since 2010. There are 1 older and 12 younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.
Robert's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.
Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link, and Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Imunon Inc executives and other stock owners filed with the SEC include: